A new case study found that an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.
There are currently 2 FDA-approved chimeric antigen receptor (CAR) T-cell therapies available in the United States, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). Both therapies are indicated to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma; however, Kymriah holds an additional indication to treat B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients.
As part of a report by the American Society of Clinical Oncology, Clinical Cancer Advances 2018, CAR T-cell therapy was named the biggest research breakthrough of 2017. Now, researchers at Moffitt Cancer Center in Tampa, Florida are looking to expand the therapy use to other cancers.
In a new phase 1 trial called THINK (Therapeutic Immunotherapy with Natural Killer Group 2D [NKG2D]), published online in Haematologica, researchers are investigating Celyad’s new CAR T therapy CYAD-01 in the treatment of acute myeloid leukemia (AML). While more than half of patients with AML go into remission after treatment with chemotherapy, many relapse due to residual leukemia cells evading both chemotherapy and the immune system. CYAD-01 genetically modifies the patients’ immune cells to express a natural killer receptor that targets leukemia cells.
A 52-year-old male patient with wild-type AML was enrolled in the THINK trial after receiving initial treatment and relapsing. CYAD-01 treatment was well-tolerated by the patient with non-related adverse events. On disease evaluation day 197 post CYAD-01 treatment, the patient had achieved complete molecular remission. To date, the AML patient has remained cancer-free for 9 months after treatment with CYAD-01, followed by a bone marrow transplant.
“It is important to note that this is the first time CAR T has induced a remission in AML. It is also the first time CAR T has been effective without the need of preconditioning chemotherapy,” said David Sallman, MD, assistant member of the department of malignant hematology at Moffitt and the case study author.
With CAR T-cell treatment, T cells are removed from a patient’s blood and then genetically modified to enable the cells to identify and specifically attack cancer cells. Once the new cells are developed, patients typically receive preconditioning chemotherapy in order to deplete their immune system and make room for the new cells. However, in the THINK study, no preconditioning chemotherapy was necessary.
“Our case study shows that CAR T therapy is a viable option for AML patients,” added Sallman. “We now need to take what we have learned in this initial study and expand the trial.”
Reference
Sallman D, Brayer J, Sagatys E, et al. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient [published online April 27, 2018]. Haematologica. doi:10.3324/haematol.2017.186742.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More